AstraZeneca | Investor Day Presentation Deck | 34 slides

AstraZeneca · 2021-09
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

34
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
introduce_nominees
04
front_matter
05
front_matter
06
The diagram uses a circular flow representing different therapeutic modalities (Immune engagers, Cell therapy, Oncolytic virus, Immuno-oncology, DNA damage resppresent_framework
Open slide detailBeat · ProblemLoop · Cost Of Inaction
07
Includes a timeline of 5 years of Presidential Symposia/Presentations.summarize
Open slide detailBeat · ProblemLoop · Cost Of Inaction
08
The slide features a stylized silhouette of a person with a molecular/cellular visualization in the chest area.front_matter
Open slide detailBeat · ProblemLoop · Cost Of Inaction
09
Clinical trial design diagram showing randomization between T-DXd and T-DM1.present_framework
Open slide detailBeat · ProductLoop · Cost Of Inaction
10
Standard clinical trial patient flow diagram.analyze_data
Open slide detailBeat · ProductLoop · Cost Of Inaction
11
Waterfall plots show best percentage change in sum of diameters from baseline for two treatment arms.analyze_data
Open slide detailBeat · ProductLoop · Cost Of Inaction
12
Kaplan-Meier survival analysis plot with a risk table below.analyze_data
Open slide detailBeat · ProductLoop · Cost Of Inaction
13
Kaplan-Meier survival analysis plot with a risk table at the bottom.analyze_data
Open slide detailBeat · ProductLoop · Cost Of Inaction
14
Clinical trial data presentation; includes 'Patients Still at Risk' table and statistical summary.analyze_data
Open slide detailBeat · ProductLoop · Cost Of Inaction
15
The table compares safety profiles of two drugs across various adverse event categories.analyze_data
Open slide detailLoop · Cost Of Inaction
16
Includes footnotes regarding patient exclusions and definitions of LVEF events.analyze_data
Open slide detailLoop · Cost Of Inaction
17
The slide highlights PFS, ORR, OS, and safety profile metrics.summarize
Open slide detailBeat · SolutionLoop · Cost Of Inaction
18
The slide uses a timeline-like arrow structure to represent lines of therapy (1L, 2L, 3L+).compare_peers
Open slide detailBeat · Solution
19
The slide features a stylized silhouette of a person with a molecular/antibody illustration inside the chest area.transition
Open slide detailBeat · Solution
20
The slide uses a chronological progression (Today, 2022, Future) to frame the drug's market expansion.summarize
Open slide detailBeat · Solution
21
The slide uses a matrix-like layout to map disease states (rows) against treatment lines (columns).plan_implementation
22
The slide features a stylized silhouette of a person with a molecular/antibody structure overlaid on the chest area.transition
Open slide detailBeat · Market Size
23
Slide presents two distinct clinical trial visualizations: a Kaplan-Meier survival curve and a waterfall plot.analyze_data
Open slide detailBeat · Market Size
24
The slide uses a color-coded system to distinguish between monotherapy (purple) and combination therapy (yellow) clinical trials.plan_implementation
Open slide detailBeat · Market Size
25
The slide presents two distinct clinical data sets: a table for PACIFIC-R and a Kaplan-Meier survival curve for the COAST trial.analyze_data
Open slide detailBeat · Market Size
26
Slide displays multiple clinical trial results (Kaplan-Meier curves and waterfall plots) across different drug combinations.analyze_data
27
The slide features a stylized silhouette of a human head and torso with biological/molecular imagery inside.state_next_steps
28
introduce_nominees
30
The slide uses a process flow diagram to map eligibility criteria to specific patient cohorts.present_framework
31
The slide uses a process flow diagram to illustrate the trial structure.present_framework
32
Clinical trial design diagram showing patient flow from enrollment to treatment arms.present_framework
33
Includes a table of clinical outcomes (PFS-10 months, ORR) and a risk table at the bottom.analyze_data